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High-dose-rate(HDR)brachytherapyisusedwithincreasingfrequencyforthetreatmentofprostatecancer.Itisatechniquewhich
allows delivery of large individual fractions to the prostate without exposing adjacent normal tissues to unacceptable toxicity. This
approach is particularly favourable in prostate cancer where tumours are highly sensitive to dose escalation and to increases in
radiotherapy fraction size, due to the unique radiobiological behaviour of prostate cancers in contrast with other malignancies. In
this paper we discuss the rationale and the increasing body of clinical evidence for the use of this technique in patients with high-
risk prostate cancer, where it is combined with external beam radiotherapy. We highlight practical aspects of delivering treatment
and discuss toxicity and limitations, with particular reference to current practice in the United Kingdom.
1.Introduction
There is an ever-increasing demand for radiation tech-
niques in the management of high-risk localised and locally
advanced prostate cancer which allow dose escalation, whilst
minimising the risks of acute and late severe toxicity. High-
dose-rate (HDR) brachytherapy is ideally suited to achieving
these goals for several reasons.
Here we discuss the history of HDR brachytherapy
for high-risk prostate cancer with relevant radiobiological
principles. We summarise important existing data and relate
these to current practice in the United Kingdom.
2.Background
Prostate cancer is the commonest malignancy in men, and in
the UK approximately 40,000 cases are diagnosed annually
[1]. Incidence is increasing, partly due to the increasing use
of the serum PSA assay in symptomatic and asymptomatic
patients. There are many patients with prostate cancer who
will not die from their disease, even without treatment in
some cases. However, patients with more aggressive forms
of the disease require an intensive approach to treatment to
maintain a normal life expectancy.
Identifying these high-risk patients has long been a topic
of debate and controversy. Improving knowledge of the
biology of prostate cancer can help to guide patients in the
clinic and is also of crucial importance to the design of
therapeutic clinical trials: the development of increasingly
aggressive treatments with the aim of cure has undoubtedly
led to improved survival outcomes over time, but the risk
of potentially serious short- and long-term iatrogenic side
eﬀects from “overtreating” patients at low risk should never
be overlooked.
Surgical and radiotherapy series, including the use of
pelvic lymphadenectomy [2, 3], have led to the identiﬁca-
tion of several factors associated with microscopic lymph
node involvement and subsequent metastatic disease. These
include serum PSA at presentation, Gleason score on biopsy,
and clinical T (tumour) stage determined by clinical exami-
nation and, in later studies, by magnetic resonance imaging.
In the UK risk is typically categorised using groupings based
on those described by D’Amico et al. (Table 1)[ 2, 4].
In addition, an estimate of risk of lymph node involve-
ment can be obtained using the Roach formula [5]:
% risk microscopic lymph node involvement
=

2
3
PSA

+[(Gleason score − 6) ×10].
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Table 1: Prostate cancer risk groups.
Group Criteria
Low risk T1-T2a and PSA ≤ 10ng/mL and
Gleason score ≤ 6
Intermediate risk T2b or PSA > 10 ≤ 20ng/mL or
Gleason score 7
High risk
≥T2c or PSA > 20ng/mL
or Gleason score ≥ 8
3. Radiotherapy in High-Risk ProstateCancer
Favourable long-term local control rates and overall survival
are seen when high-risk patients are treated with primary
radiotherapy in combination with the addition of androgen
suppression, prior to and after radiotherapy [6–9]. This
approach has therefore become a standard of care for
patients with high-risk disease. The duration of long-term
adjuvant androgen suppression after radiotherapy varies in
published studies, but improvements in progression-free
survival have been demonstrated where 2 or 3 years of
androgen suppression are used, compared with durations of
6 months or less [8, 9].
Furthermore,althoughnodirectcomparisonwithradio-
therapy has been made, surgical series have demonstrated
that following radical prostatectomy a proportion of high-
risk patients will later relapse following surgery, particularly
where surgical margin positivity and/or extraprostatic dis-
ease are present [10–12]. Some of these patients may be
cured with radiotherapy to the prostate bed at relapse, but
at the expense of exposure to potential serious long-term
toxicities from both surgery and external beam radiotherapy
(EBRT). Prostatectomy for patients with high-risk disease is
thus considered only in carefully selected patients [13].
Theoptimalradiotherapytreatmentvolumesforpatients
with high-risk disease remain unclear. There are data that
support the practice of moderate-dose whole pelvic radio-
therapy (WPRT) in this setting [14, 15], with a high-dose
“boost” to the prostate itself. The relative contributions of
WPRT and long-term androgen suppression are diﬃcult to
separate, however [15], and this approach is not without
acuteandlatetoxicity,particularlygastrointestinalcomplica-
tions. Studies to further evaluate the role of WPRT in high-
risk patients are ongoing.
4. Background andRationalefor
HDRBrachytherapy
4.1. Dose Escalation. In vitro and clinical studies show
that there is correlation between prostate cancer survival
endpoints and increasing radiation dose [16–18]. However,
in practice this may be at the expense of increased toxicity,
due to exposure of organs at risk where conventional
conformal megavoltage photon external beam radiotherapy
(EBRT) is employed.
For example, a 2002 randomised study of 305 patients
treated at the MD Anderson Cancer Centre [18]d e m o n -
strated a reduction in clinical and biochemical failure rate at
6-year followup (64% versus 70%, P = 0.003) in patients
who had received 78Gy compared with those who had
received 70Gy external beam therapy to the prostate, across
a range of risk groups. However, it was noted that where
more than 25% of the rectum received a dose of 70Gy or
greater, the incidence of late rectal toxicity of grade 2 or
greater increased to 30%. It is frequently not possible to limit
the rectal dose using conventional EBRT techniques alone.
Similar outcomes are seen in a number of other large phase
III dose escalation studies using EBRT alone [16, 17].
4.2. Radiobiological Principles. Radiobiological research
demonstrates that the probabilities of acute and late ra-
diotherapy reactions vary between body tissues and tumours
and between diﬀerent radiotherapy dose-fractionation
schedules. In particular, the likelihood of a late radiotherapy
reaction or response is more dependent than acute reactions
on the fraction size (dose per fraction) for a given total dose
of radiation [19].
The α/β ratio, a means of expressing the sensitivity
of a particular tissue to altered fraction size, is used to
estimate the impact of a given schedule on tumour control
and toxicity and enables comparisons to be made between
schedules. Tissues and tumours with a low α/β ratio have
a higher relative sensitivity to changes in fraction size than
those with a high α/β ratio.
Fast-growing tumours have been demonstrated to have
high α/β ratio (i.e., tumour responses are less dependent on
fraction size; they may be more dependent on overall treat-
ment time), whereas increasing evidence exists to support
a low α/β ratio for prostate cancer, which may be as low
as 1.5Gy, in which case a hypofractionated approach (large
doses in a small number of fractions) is favoured for optimal
tumour control [20–23].
The EQD2 formula is frequently used to estimate the
equivalent dose at 2Gy per fraction for a given schedule:
EQD2 = D ×

d +α/β


2+α/β
,( 2 )
where D is the total dose, d dose per fraction, and the α/β
ratio for a given tissue is used.
HDR brachytherapy lends itself to the delivery of a large
radiation dose to the prostate in a small number of fractions
(hypofractionation). For practical reasons (primarily the
requirement to limit the number of invasive procedures and
duration of patient immobility) it has in fact been necessary
to deliver treatment in this way.
For example, a typical radical EBRT schedule for prostate
cancer is given as 74Gy, using a fraction size of 2Gy. Table 2
illustrates the EQD2 estimations for the prostate for a variety
of schedules used in published HDR brachytherapy series,
assuming an α/β ratio of 1.5Gy (see Table 2).
These doses are not achievable using EBRT alone, even
with the use of more modern intensity-modulated tech-
niques.
4.3. Procedures. At our centre HDR brachytherapy is deliv-
ered using the following technique.Advances in Urology 3
Table 2: Estimated equivalent doses (2Gy per fraction) for published HDR schedules using the EQD2 formula, assuming α/β for prostate
cancer of 1.5Gy [19].
Author Schedule EQD2 prostate
(α/β 1.5Gy)
Galalae et al. [36] 50Gy WPRT, 40Gy prostate EBRT, 2 fractions HDR (9Gy per fraction) 94Gy
˚ Astr¨ om et al. [30] 50Gy in 25 fractions EBRT, 2 fractions HDR (10Gy per fraction) 115.7Gy
Martinez et al. [28] 46Gy in 23 fractions EBRT, 2 fractions HDR (11.5Gy per fraction) 131.4Gy
Hoskin et al. [32] 55Gy in 20 fractions EBRT, 2 fractions HDR (8.5Gy per fraction) 115.4Gy
Under sterile conditions and with regional anaesthesia
and following urethral catheterisation, up to 20 blind-ended
needles are inserted into and adjacent to the prostate. To
guide needle insertion, a transrectal ultrasound (TRUS)
probe with stepping unit and template are used. This
technique is similar to that originally described for the
insertion of low-dose rate 125I seeds [24].
2mm axial CT images of the pelvis are taken with
the implant in situ. The prostate, rectum, and urethra are
outlined using specialist planning software, and a planning
target volume is created by adding a 3mm margin around
the prostate in all dimensions.
Source dwell positions and times are determined using
specialist planning software, in order to deliver 15Gy to the
PTV in a single fraction, whilst doses to organs at risk are
limited according to published guidelines [25]. Treatment
is delivered using a single 192Ir source via an afterloading
unit. Following treatment the needles are removed, and
once haemostasis is achieved the urinary catheter is also
removed.
There is no permanent implant with this technique; thus,
no long-term radiation protection issues exist. A temporary
implant also allows precise dosimetric calculations, so that
the technique be used in combination with EBRT. This
combination strategy is of particular relevance to high-risk
patients, where it may be necessary to extend the treatment
volume to include areas at high risk of microscopic spread
(seminal vesicles and/or pelvic lymph nodes) to a moderate
dose, whilst administering a high-dose boost to the prostate.
It is not possible to treat these extended “prophylactic”
volumes with brachytherapy alone.
4.4. Clinical Data. Although previously some centres had
reported the use of iridium wire implants, the modern HDR
brachytherapy prostate “boost” was ﬁrst developed in the
late 1980s in combination with external beam radiotherapy
(EBRT) to the whole pelvis in intermediate- and high-risk
patients. In an early study by the Michigan group [26], three
fractions of HDR brachytherapy were given concurrently
with EBRT in weeks 1, 2, and 3 of treatment. Brachytherapy
was well tolerated, and 9 of the ﬁrst 10 patients who
underwent planned rebiopsy at 18 months after treatment
w e r ef o u n dt oh a v en or e s i d u a lc a n c e r .
With longer-term followup and comparison with a
matched cohort [27], data emerged from this group to
suggest superiority of HDR brachytherapy in this context,
at least in terms of biochemical control, due to the much
increased biologically eﬀective dose delivered using the
brachytherapy technique. An interim analysis conﬁrmed
i m p r o v e db i o c h e m i c a lc o n t r o lr a t e sw i t ht w ov e r s u st h r e e
fractions and with increased dose per fraction [28].
Data from this group were combined for analysis with
those from two other institutions to establish the largest
published series of over 600 patients [29]. A 73% 10-year
biochemical control rate was observed across all treated
groups, with disease-free survival of 49%, and encouraging
resultseveninpatientsathighrisk(69%biochemicalcontrol
at 5 years). Although a variety of doses and schedules
were employed between centres, encouragingly results were
consistent.
Similarly, a Swedish group [30] reported 4-year follow-
up data in 2005 on over 200 patients treated with EBRT to
50Gy in 25 fractions with two fractions of HDR brachyther-
apy of 10Gy each, in an interval midway through the EBRT.
In the high-risk group (47 patients) overall 5-year biological
no evidence of disease (bNED) was 61%.
Again, 10-year follow-up data from California (209
patients) [31] reported 69% bNED for the high-risk group.
The only prospective randomised controlled trial of
EBRT alone versus EBRT with HDR brachytherapy boost,
in 220 patients, reported signiﬁcantly improved biochemical
relapse-free survival in the brachytherapy group (5.1 years
versus 4.3 years at median 30-month followup) with a
reduction in acute rectal toxicity [32]. Although the dose-
fractionation schedule in the EBRT arm of this study may
now be considered suboptimal, these results do support
previous data and the principles discussed and have sup-
ported further work evaluating dose escalation with HDR
brachytherapy monotherapy in lower-risk patients [33]. It
is recognised, however, that a direct comparison of HDR +
EBRT and dose-escalated EBRT in intermediate- and high-
risk patients has not been carried out.
A systematic review published in 2009 [34]c o m p a r e d
results from studies evaluating high-dose (>75Gy) EBRT,
HDR brachytherapy with EBRT and low-dose rate seed
brachytherapy with EBRT. Superior results, in terms of
progression-free survival and overall survival, were seen
for HDR brachytherapy and EBRT when compared with
other techniques. This is likely to be due to the high doses
achieved—it is noted that due to dose gradients within
an HDR implant, there may be regions which receive far
greaterdosesthanthoseprescribed.Theauthorsofthispaper
acknowledge that although every attempt has been made to
account for confounding factors, marked variations between
methods and deﬁnitions of survival endpoints in published
studies mean that these results should be interpreted with4 Advances in Urology
a degree of caution; nevertheless these data lend further
support to the practice of HDR brachytherapy.
4.5.SingleFractionHDRBrachytherapy. Theincreasingbody
of evidence to support hypofractionation has led to the
development of an “ultra-hypofractionated” single fraction
HDR boost. This has obvious potential biological, practical,
and cost-saving advantages, and any geometric uncertainty
is virtually eliminated as there is no risk of interfraction
variability.
The EQD2 to the prostate for a single fraction of 15Gy,
using a presumed α/β ratio of 1.5Gy, is estimated at 70Gy
using the formula described. When combined with EBRT,
an equivalent dose of up to 120y in 2Gy fractions is
achievable.
The use of single fraction HDR brachytherapy in com-
bination with EBRT in intermediate-risk patients has been
reported [35]. At relatively short followup (median 1.14
years) biochemical control rates were excellent and observed
toxicity acceptable; there was a notable lack of acute and late
gastrointestinal toxicity. Genitourinary toxicity is far more
common, partly due to diﬃculty avoiding high doses to
the prostatic urethra; however, no severe late genitourinary
toxicity has yet been observed in this cohort of 125 patients.
There has been much interest in this technique, which
hasalsobeenadoptedinanumberofcentresforthemanage-
ment of high-risk patients in combination with pelvic EBRT.
Furtherworkandfollowuparerequired,however,toevaluate
the true long-term consequences of ultra-hypofractionation,
and caution should be exercised particularly in patients with
preexisting urinary symptoms (see Section 4.6).
4.6. Toxicity. Acutely, HDR brachytherapy commonly leads
to an increase in urinary symptoms as measured by the IPSS
score [32, 35–38]. However, this is generally short lived, and
catheterisation is a rare event. Relatively high rates of late
grade 3 urinary toxicity have been noted in patients who
undergo postradiotherapy transurethral resection (TUR),
and in those with large preexisting defects from previous
TUR [31] HDR brachytherapy is relatively contraindicated,
therefore, in patients with signiﬁcant obstructive lower uri-
nary tract symptoms prior to treatment [25]. Incontinence is
an infrequent event.
Deterioration in potency is reported after HDR brachy-
therapy and EBRT in high-risk patients. However, there is
much variation in method of assessment and the impact of
androgendeprivationtherapyisdiﬃculttoseparatefromthe
eﬀectsofradiotherapy.Therateoferectiledysfunctioninthis
patient group is however high and increases with time (up to
76% at 7 years has been reported) [25].
T h e r ei sn od o u b tt h a ta c u t ea n dl a t er e c t a lt o x i c t yr a t e s
are low following HDR brachytherapy. In the randomised
trial [32], a signiﬁcant reduction in acute rectal discharge
was seen in the brachytherapy group, and in the single
fraction study [35] only 6.5% of patients experienced acute
grade 2 or greater gastrointestinal toxicity, with 10% grade
2 late toxicity. No severe late toxicity has been reported in
this group, but again the short reported follow-up period is
noted.
4.7. HDR Brachytherapy in UK Practice. HDR brachytherapy
is an attractive treatment option for patients with high-risk
disease, with the potential to increase dose and thus improve
tumour control, as well as reducing toxicity and, from a
practical viewpoint, reducing overall treatment time. It is
becoming increasingly available and is currently practised in
a number of UK centres. Its use is supported by the National
Institute for Health and Clinical Excellence (NICE) [4]f o r
use in combination with external beam radiotherapy in
appropriately selected intermediate- and high-risk patients
with nonmetastatic prostate cancer [4, 25].
The potential advantages of HDR brachytherapy over
EBRT alone should be discussed with appropriate patients.
It is important, however, that clinicians and patients alike
are aware of the limitations of current data, when making
decisions on the optimum treatment approach.
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